Evidence map›Paper›PMID 37040038›Full record

ArticleBulletin of experimental biology and medicine2023

Online Service with Automated Interpretation of Sequencing Data and Prediction of Pyrazinamide Resistance in Mycobacterium tuberculosis.

V V Sinkov, I G Kondratov, O B Ogarkov, S N Zhdanova, N A Sokolnikova, P A Khromova, E A Orlova, L V Rychkova, L I Kolesnikova

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

V V SinkovScientific Center for Family Health and Human Reproduction Problems, Irkutsk, Russia.
I G KondratovScientific Center for Family Health and Human Reproduction Problems, Irkutsk, Russia.
O B OgarkovScientific Center for Family Health and Human Reproduction Problems, Irkutsk, Russia. obogarkov@sbamsr.irk.ru.
S N ZhdanovaScientific Center for Family Health and Human Reproduction Problems, Irkutsk, Russia.
N A SokolnikovaIrkutsk Regional Clinical Tuberculosis Hospital, Irkutsk, Russia.
P A KhromovaScientific Center for Family Health and Human Reproduction Problems, Irkutsk, Russia.
E A OrlovaScientific Center for Family Health and Human Reproduction Problems, Irkutsk, Russia.
L V RychkovaScientific Center for Family Health and Human Reproduction Problems, Irkutsk, Russia.
L I KolesnikovaScientific Center for Family Health and Human Reproduction Problems, Irkutsk, Russia.
Scientific Center of Family Health Problems and Human Reproduction · RUIrkutsk Regional Clinical Hospital · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pyrazinamide plays an important role in the treatment of tuberculosis. However, the microbiological test for pyrazinamide resistance is more complex and less reliable than testing of susceptibility to other anti-tuberculosis drugs due to the need to grow the pathogen at pH 5.5. Identification of mutations that cause resistance to anti-tuberculosis drugs can replace microbiological methods. Mutations in the pncA gene are responsible for the main mechanism of the resistance to pyrazinamide and are found in more than 90% of resistant strains. However, the genetic method for determining drug susceptibility is very complex, because mutations leading to pyrazinamide resistance are diverse and scattered throughout the gene. We have developed a software package for automatic data interpretation and prediction of the resistance to pyrazinamide based on Sanger sequencing results. The effectiveness of detection of pyrazinamide resistance in 16 clinical samples was compared using the BACTEC MGIT 960 automated system and pncA gene Sanger sequencing with automated analysis of the results. A significant advantage of the developed method over a single microbiological study was shown, due to greater reliability of the results irrespective of the purity of isolates.

Indexed as

Mycobacterium tuberculosisPyrazinamideAmidohydrolasesAntitubercular AgentsMicrobial Sensitivity TestsMutationReproducibility of ResultsAmidohydrolasesAntitubercular AgentsPyrazinamideMycobacterium tuberculosisonline servicepncAresistance to pyrazinamidesequencing

Identifiers

PMID37040038
OpenAlexW4364352054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.